Activation of Pro-apoptotic p38-MAPK Pathway in the Prostate Cancer Cell Line M12 Expressing a Truncated IGF-IR

 

 Buy Article Permissions and Reprints

Abstract

The type I insulin-like growth factor receptor (IGF-IR) plays a critical role in signaling survival and proliferation in many cell types. Activation of IGF-IR by its ligands promotes cell proliferation via mitogen-activated protein kinase (MAPK) cascade and cell survival via phosphoinositide 3-kinase (PI3K) cascade. The IGF-IR emerges as a powerful growth factor for many tumor cells. A truncated IGF-IR 486/STOP, described as a dominant negative IGF-IR mutant, was shown to induce apoptosis and inhibit tumor growth in vivo while endogenous IGF-IR was activated. To investigate the mechanism(s) of the action of 486/STOP, we have introduced 486/STOP into the prostate tumor model cell line M12 and its derivative M12lisn that expresses high levels of wild type IGF-IR. We have found that 486/STOP induces apoptosis in M12 and M12lisn cells in culture and that 486/STOP acts through activation of the pro-apoptotic p38-MAPK without interfering with wild type IGF-IR activation. In addition, our results have indicated that 486/STOP induced activation of p38-MAPK increases through activation of endogenous IGF-IR. These data suggest that activation of the IGF-IR by 486/STOP can selectively enhance the previously reported IGF-IR pro-apoptotic signaling pathways.

References

• 1 Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity.  Cell. 1990;  61 203-212
  CrossrefPubMedGoogle Scholar
• 2 Ullrich A, Gray A, Tam A W, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le B on, Kathuria S, Chen E, Jakobs S, Francke U, Ramachandran J, Fujita-Yamagichi Y. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity.  EMBO J. 1986;  5 2503-2512
  PubMedGoogle Scholar
• 3 Baserga R. The insulin-like growth factor I receptor: a key to tumor growth.  Cancer Res. 1995;  55 249-252
  PubMedGoogle Scholar
• 4 LeRoith D, Baserga R, Helman L, Roberts C T Jr. Insulin-like growth factors and cancer.  Ann Intern Med. 1995;  122 54-59
  PubMedGoogle Scholar
• 5 Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity.  Lab Invest. 1995;  73 311-331
  PubMedGoogle Scholar
• 6 Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis.  Biochim Biophys Acta. 1997;  1332 F105-126
  PubMedGoogle Scholar
• 7 Butler A A, Yakar S, Gewolb I H, Karas M, Okubo H, LeRoith D. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology.  Comp Biochem Physiol B Biochem Mol Biol. 1998;  121 19-26
  PubMedGoogle Scholar
• 8 Parrizas M, Saltiel A R, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3’-kinase and mitogen-activated protein kinase pathways.  J Biol Chem. 1997;  272 154-161
  CrossrefPubMedGoogle Scholar
• 9 Brunet A, Bonni A, Zigmond M J, Lin M Z, Juo P, Hu L S, Anderson M J, Arden K C, Blenis J, Greenberg M E. Akt Promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor.  Cell. 1999;  96 857-868
  CrossrefPubMedGoogle Scholar
• 10 Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB.  J Biol Chem. 1998;  273 32 377-32 379
  PubMedGoogle Scholar
• 11 Moule S K, Welsh G I, Edgell N J, Foulstone E J, Proud C G, Denton R M. Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and βadrenergic agonists in rat epididymal fat cells.  J Biol Chem. 1997;  272 7713-7719
  CrossrefPubMedGoogle Scholar
• 12 Cardone M H, Henning N R, Stennicke R, Salvesenet G S. et al . Regulation of cell death protease caspase-9 by phosphorylation.  Science. 1998;  282 1318-1321
  CrossrefPubMedGoogle Scholar
• 13 Datta S R, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg M E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.  Cell. 1997;  91 231-241
  CrossrefPubMedGoogle Scholar
• 14 Burgaud J, Resnicoff M, Baserga R. Mutant IGF-I receptors as dominant negatives for growth and transformation.  Biophs Biochem Res Commun. 1995;  214 475-481
  PubMedGoogle Scholar
• 15 Prager D, Li H L, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant.  Proc Natl Sci USA. 1994;  91 2181-2185
  PubMedGoogle Scholar
• 16 D’Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis.  Cancer Res. 1996;  56 4013-4020
  PubMedGoogle Scholar
• 17 Reiss K, D’Ambrosio C, Tu X, Tu C, Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect.  Clin Cancer Res. 1998;  4 2647-2655
  PubMedGoogle Scholar
• 18 Dunn S E, Ehrlich M, Sharp N J, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett J C. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.  Cancer Res. 1998;  58 3353-3361
  PubMedGoogle Scholar
• 19 Reiss K, Tu X, Romano G, Peruzzi F, Wang J Y, Baserga R. Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors.  Clin Cancer Res. 2001;  7 2134-2144
  PubMedGoogle Scholar
• 20 Plymate S S, Bae V L, Maddison L, Quinn L S, Ware J L. Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells.  Endocrinology. 1997;  138 1728-1735
  CrossrefPubMedGoogle Scholar
• 21 Bae V L, Jackson-Cook C K, Maygarden S J, Plymate S R, Chen J, Ware J L. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line.  Prostate. 1998;  34 275-282
  CrossrefPubMedGoogle Scholar
• 22 Guo N, Ye J J, Liang S J, Mineo R, Li S L, Giannini S, Plymate S R, Sikes R A, Fujita-Yamaguchi Y. The role of insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models.  Growth Horm IGF Res. 2003;  13 44-53
  PubMedGoogle Scholar
• 23 Gallo K A, Johnson G L. Mixed-lineage kinase control of JNK and p38 MAPK pathways.  Nat Rev Mol Cell Biol. 2002;  3 663-672
  CrossrefPubMedGoogle Scholar
• 24 Tanaka Y, Gavrielides M V, Mitsuuchi Y, Fujii T, Kazanietz M G. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through the activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003
  Google Scholar
• 25 Bowen C, Birrer M, Gelmann E P. Retinoblastoma protein-mediated apoptosis after gamma-irradiation.  J Biol Chem. 2002;  277 44 969-44 979
  PubMedGoogle Scholar
• 26 Heron-Milhavet L, Karas M, Goldsmith C M, Baum B J, LeRoith D. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair.  J Biol Chem. 200;  276 18 185-18 192
  PubMedGoogle Scholar
• 27 O’Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan G I, Baserga R, Blattler W A. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis.  Mol Cell Biol. 1997;  17 427-435
  PubMedGoogle Scholar

S. R. Plymate, M.D.

Department of Medicine, Division of Gerontology and Geriatric Medicine · University of Washington

Box 359755 · 325 9th Ave. · Seattle · WA98104 · USA

Phone: + 1 (206) 341-5336 ·

Fax: + 1 (206) 341-5302

Email: splymate@u.washington.edu